Kinetics of plasma and erythrocyte metformin after acute administration in healthy subjects
- PMID: 12909816
- DOI: 10.1016/s1262-3636(07)70037-x
Kinetics of plasma and erythrocyte metformin after acute administration in healthy subjects
Abstract
Objectives: Although the existence of a deep compartment for metformin has long been hypothesized, there is still little direct information concerning metformin distribution in individual tissues in man. The only available study involves chronic metformin therapy. In that study, the measurement of metformin in erythrocytes provided a reliable indicator of metformin distribution and of potential accumulation. To determine the kinetics of metformin in plasma and in erythrocytes after acute oral administration, we performed the present study in healthy subjects after a single oral dose of metformin and compared the pharmacokinetics parameters in erythrocytes to those in plasma.
Methods: Six nondiabetic participants took the study dose of 850 mg metformin at 8: 00 AM after a non-standardized breakfast (i.e., as recommended in clinical practice). Blood samples were collected for metformin measurement in plasma and in erythrocytes at 0, 1, 2, 3, 4, 6, 9, 24, 33, 48, 57, and 72 h.
Results: Maximum metformin concentration was attained at 3.0 +/- 0.3 h in plasma and 4.7 +/- 0.5 h in erythrocytes. This difference was not significant. Metformin concentrations peaked at a maximum almost 6 times higher in plasma than in erythrocytes (1.7 +/- 0.1 and 0.3 +/- 0.0 mg/l, respectively). However, because the elimination half-life of metformin was much longer in erythrocytes (23.4 +/- 1.9 h vs. 2.7 +/- 1.2 h), there was no difference in area under the curve between plasma and erythrocytes. The distribution volume (plasma) was calculated to be 146 +/- 11 l. Plasma and erythrocytes concentration-time curves showed that metformin was not detectable in plasma 24 hours after the oral administration, while it remained detectable in erythrocytes up to 48 hours. Metformin concentrations crossed approximately 13 hours after having reached their maximum values in plasma, approximately 16 h after metformin intake.
Conclusion: Having demonstrated the rapid elimination of metformin from plasma and its slow disappearance from erythrocytes, the presents results should contribute to adjustment of metformin dosage to renal function, assessment of drug compliance, and retrospective analysis (when blood samples are drawn with delay) of the link between metformin and development of lactic acidosis. Most importantly, the present findings should help to ascertain the optimal dosage of metformin, particularly in elderly patients.
Similar articles
-
Unexpectedly long half-life of metformin elimination in cases of metformin accumulation.Diabet Med. 2016 Jan;33(1):105-10. doi: 10.1111/dme.12959. Epub 2015 Oct 16. Diabet Med. 2016. PMID: 26337524
-
Measurement of metformin concentration in erythrocytes: clinical implications.Diabetes Obes Metab. 2003 Mar;5(2):93-8. doi: 10.1046/j.1463-1326.2003.00241.x. Diabetes Obes Metab. 2003. PMID: 12630933
-
Influences of organic cation transporter polymorphisms on the population pharmacokinetics of metformin in healthy subjects.AAPS J. 2013 Apr;15(2):571-80. doi: 10.1208/s12248-013-9460-z. Epub 2013 Feb 16. AAPS J. 2013. PMID: 23417334 Free PMC article.
-
Clinical pharmacokinetics of metformin.Clin Pharmacokinet. 1996 May;30(5):359-71. doi: 10.2165/00003088-199630050-00003. Clin Pharmacokinet. 1996. PMID: 8743335 Review.
-
A justification for less restrictive guidelines on the use of metformin in stable chronic renal failure.Diabet Med. 2014 Sep;31(9):1032-8. doi: 10.1111/dme.12515. Diabet Med. 2014. PMID: 24909998 Review.
Cited by
-
Involvement of organic cation transporter 3 (Oct3/Slc22a3) in the bioavailability and pharmacokinetics of antidiabetic metformin in mice.Drug Metab Pharmacokinet. 2016 Oct;31(5):385-388. doi: 10.1016/j.dmpk.2016.04.005. Epub 2016 Apr 30. Drug Metab Pharmacokinet. 2016. PMID: 27569291 Free PMC article.
-
Factors contributing to variability in metformin concentration in polycystic ovary syndrome.Croat Med J. 2024 Apr 30;65(2):138-145. doi: 10.3325/cmj.2024.65.138. Croat Med J. 2024. PMID: 38706239 Free PMC article.
-
Influence of Plantago ovata husk (dietary fiber) on the bioavailability and other pharmacokinetic parameters of metformin in diabetic rabbits.BMC Complement Altern Med. 2017 Jun 7;17(1):298. doi: 10.1186/s12906-017-1809-x. BMC Complement Altern Med. 2017. PMID: 28592281 Free PMC article.
-
Metformin use is associated with a reduced risk of mortality in patients with diabetes hospitalised for COVID-19.Diabetes Metab. 2021 Sep;47(5):101216. doi: 10.1016/j.diabet.2020.101216. Epub 2020 Dec 10. Diabetes Metab. 2021. PMID: 33309936 Free PMC article.
-
Is Metformin a Possible Beneficial Treatment for Psoriasis? A Scoping Review.J Pers Med. 2021 Mar 30;11(4):251. doi: 10.3390/jpm11040251. J Pers Med. 2021. PMID: 33808460 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical